Filing Flows › Comparisons › SRPT vs INDV
Sarepta Therapeutics vs Indivior Pharmaceuticals: SRPT and INDV compared
Sarepta Therapeutics is the larger company: $381M of revenue in its latest quarter (Q3 2026) against $356M for Indivior Pharmaceuticals (Q3 2026). Indivior Pharmaceuticals is growing faster (+13% against -4% a year earlier). Indivior Pharmaceuticals is more profitable, with an operating margin of 50.6% against -2.4%.
Where the money goes: SRPT and INDV
Sarepta Therapeutics (SRPT) · Q3 2026
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Indivior Pharmaceuticals (INDV) · Q3 2026
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
| Sarepta Therapeutics (SRPT) | Indivior Pharmaceuticals (INDV) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $381M | $356M |
| Revenue growth, Y/Y | -4% | +13% |
| Gross margin | — | 85.7% |
| Operating margin | -2.4% | 50.6% |
| Net earnings | −$28.5M | $137M |
| Net margin | -7.5% | 38.5% |
| Operating cash flow | $60.0M | $97.0M |
| Free cash flow | $57.0M | $83.0M |
| Market value | $1.9B | $4.4B |
| P/E | — | 10.1× |
| Analysts’ mean target | $21.68 | $49.50 |
Where the revenue comes from
Sarepta Therapeutics
- Pmo Products: $240M (63%)
- Elevidys: $83.5M (22%)
- Other revenues: $57.6M (15%)
Questions
Which is bigger, Sarepta Therapeutics or Indivior Pharmaceuticals?
Sarepta Therapeutics is the larger company: $381M of revenue in its latest quarter (Q3 2026) against $356M for Indivior Pharmaceuticals (Q3 2026).
Is Sarepta Therapeutics or Indivior Pharmaceuticals growing faster?
Indivior Pharmaceuticals is growing faster (+13% against -4% a year earlier).
Which is more profitable, Sarepta Therapeutics or Indivior Pharmaceuticals?
Indivior Pharmaceuticals is more profitable, with an operating margin of 50.6% against -2.4%.
More: Sarepta Therapeutics earnings · how Sarepta Therapeutics makes money · Indivior Pharmaceuticals earnings · how Indivior Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.